单次与标准剂量产前糖皮质激素对晚期早产新生儿结局的等效性:一项二次分析
该研究为产前晚期早产糖皮质激素试验的二次分析,纳入1083例仅接受单次产前糖皮质激素或安慰剂且24小时内分娩者。单次产前糖皮质激素组与安慰剂组的主要呼吸结局(校正RR 1.12,95%CI 0.85-1.47)和呼吸窘迫综合征发生率(校正RR 1.47,95%CI 0.95-2.26)均无差异。但研究把握度不足以检测治疗有效性。
要点
- 单次产前糖皮质激素与安慰剂相比,主要呼吸结局无差异(校正RR 1.12,95%CI 0.85-1.47)。
- 呼吸窘迫综合征发生率两组无差异(校正RR 1.47,95%CI 0.95-2.26)。
- 按随机化至分娩间隔12小时分层探索,未显示与主要呼吸结局率降低相关。
核心结论
- 在晚期早产妊娠中接受产前糖皮质激素且在第二剂前分娩者,新生儿呼吸疾病发生率与安慰剂相比无差异。
- 但该研究把握度不足以检测治疗有效性。
研究设计与样本
- 产前晚期早产糖皮质激素试验的二次分析。
- 纳入母试验中仅接受单次产前糖皮质激素或安慰剂且24小时内分娩的全部个体。
- 母试验共2831例,1083例(38.3%)符合纳入标准;其中539例(49.8%)接受单次产前糖皮质激素,544例(50.2%)接受单次安慰剂。
- 主要结局为72小时内呼吸支持复合结局,包括持续气道正压或高流量鼻导管≥2小时、吸入氧分数≥30%的氧疗≥4小时或机械通气。
主要发现
- 单次产前糖皮质激素组与安慰剂组的主要呼吸结局率无差异(校正风险比1.12;95%置信区间0.85-1.47)。
- 单次产前糖皮质激素组与安慰剂组的呼吸窘迫综合征率无差异(校正风险比1.47;95%置信区间0.95-2.26)。
- 按随机化至分娩间隔12小时分层探索,未显示与主要呼吸结局率降低相关。
- 安慰剂组与产前糖皮质激素组的人口学和临床特征相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该研究把握度不足以检测治疗有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recent paradigm shift of treating individuals at risk of late preterm birth with antenatal corticosteroids warrants an assessment of the effect of single dosage. OBJECTIVE: To compare outcomes of neonates born in the late preterm period (34.0-36.6 weeks) after a single dose of antenatal corticosteroids vs placebo. STUDY DESIGN: We performed a secondary analysis of the Antenatal Late Preterm Steroids trial. All individuals enrolled in the parent trial who received only a single dose of either antenatal corticosteroids or placebo and delivered within 24 hours were included. Primary outcome was a composite of respiratory support at 72 hours, including continuous positive airway pressure or high-flow nasal cannula ≥2 hours, oxygen with an inspired fraction of ≥30% for ≥4 hours, or mechanical ventilation. RESULTS: Of the 2831 individuals in the parent trial, 1083 (38.3%) met inclusion criteria; of them, 539 (49.8%) received a single dose of antenatal corticosteroids and 544 (50.2%) a single placebo dose. The placebo and antenatal corticosteroids groups had similar demographic and clinical characteristics. There was no difference in the rate of the primary respiratory outcome (adjusted risk ratio, 1.12; 95% confidence interval, 0.85-1.47) or in the rate of respiratory distress syndrome (adjusted risk ratio, 1.47; 95% confidence interval, 0.95-2.26) between those who received a single antenatal corticosteroids dose and placebo. An exploratory stratification by randomization-to-delivery intervals of 12-hour increments also showed no association with lower primary respiratory outcome rates. CONCLUSION: In individuals with late preterm birth pregnancies who received antenatal corticosteroids and delivered before a second dose, there were no differences in neonatal respiratory morbidities compared with placebo. However, this study is not powered to detect treatment efficacy.
引用
- Bart Y, Chauhan SP, Fishel Bartal M, et al. Equivalence of single and standard doses of antenatal corticosteroids for late preterm neonatal outcomes: insights from a secondary analysis. Am J Obstet Gynecol. 2024. PMID: 38588964. doi:10.1016/j.ajog.2024.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。